公开(公告)号：WO2018215580A1

公开(公告)日：2018-11-29

申请号：PCT/EP2018/063611

申请日：2018-05-24

Applicant: FORMYCON AG

Inventor： FIEDLER, Bernd ,  BROCKMEYER, Carsten ,  SIGL, Rainer

IPC: B65B55/10 ,  A61L2/20

CPC classification number: A61L2/0094 ,  A61L2/206 ,  A61L2/208 ,  A61L2202/18 ,  A61L2202/21 ,  A61L2202/23 ,  A61M5/001

Abstract: The present invention relates to methods for sterilizing a prefilled plastic syringe containing a liquid formulation of a VEGF antagonist by exposing the prefilled syringe to nitrogen dioxide, ethylen oxide or vaporized hydrogen peroxide. The present invention further relates to a prefilled plastic syringe which is suitable to be sterilized by this method.

公开(公告)号：WO2021123202A1

公开(公告)日：2021-06-24

申请号：PCT/EP2020/087071

申请日：2020-12-18

Applicant: FORMYCON AG

Inventor： SIGL, Rainer ,  SCHOTT, Katharina Maria

IPC: A61K9/00 ,  A61K39/395 ,  A61K47/26 ,  A61K47/12 ,  A61K47/18 ,  C07K16/28 ,  A61K39/39591 ,  A61K47/183 ,  A61K9/0019 ,  C07K16/2818 ,  C07K2317/24 ,  C07K2317/94

Abstract: The present invention relates to pharmaceutical compositions of an anti-PD1 antibody comprising a buffer, a sugar or sugar alcohol and a surfactant.

公开(公告)号：WO2019020777A1

公开(公告)日：2019-01-31

申请号：PCT/EP2018/070363

申请日：2018-07-26

Applicant: FORMYCON AG

Inventor： SIGL, Rainer ,  MAX, Stefanie

IPC: A61K9/00 ,  A61K38/17 ,  A61K39/395 ,  A61K31/513 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/18 ,  A61K47/26

CPC classification number: A61K9/0048 ,  A61K9/0019 ,  A61K38/179 ,  A61K45/06 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/183 ,  A61K47/26 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/55 ,  C07K16/22 ,  C07K2317/55 ,  C07K2319/30 ,  C07K2319/32

Abstract: The present invention relates to liquid pharmaceutical compositions of a VEGF antagonist for intravitreal administration comprising a histidine buffer or a dicarboxylic acidbuffer selected from malic acid buffer, succinate buffer and maleic acid buffer, an inorganic salt, a carbohydrate and a non-ionic surfactant. The composition may also contain methionine.

公开(公告)号：WO2017129685A1

公开(公告)日：2017-08-03

申请号：PCT/EP2017/051662

申请日：2017-01-26

Applicant: FORMYCON AG

Inventor： SIGL, Rainer

IPC: A61K9/00 ,  A61K38/18

CPC classification number: A61K9/0019 ,  A61K9/0048 ,  A61K9/0051 ,  A61K38/179 ,  A61K47/02 ,  A61K47/10 ,  A61K47/26

Abstract: The present invention relates to liquid pharmaceutical compositions of a VEGF antagonist for intravitreal administration comprising a histidine buffer, an inorganic salt, a carbohydrate and a polysorbate.

Abstract translation: 本发明涉及用于玻璃体内施用的包含组氨酸缓冲液，无机盐，碳水化合物和聚山梨酯的VEGF拮抗剂的液体药物组合物。

公开(公告)号：WO2015071348A1

公开(公告)日：2015-05-21

申请号：PCT/EP2014/074464

申请日：2014-11-13

Applicant: FORMYCON AG

Inventor： SIGL, Rainer

IPC: A61K9/00 ,  A61K39/00 ,  A61K9/08

CPC classification number: C07K16/22 ,  A61K9/0048 ,  A61K9/08 ,  A61K39/00 ,  A61K39/39591 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/76

Abstract: The present invention relates to liquid pharmaceutical formulations for intravitreal injection of an anti-VEGF antibody which does not contain saccharides for use in the treatment of age-related macular degeneration.

Abstract translation: 本发明涉及用于玻璃体内注射不含用于治疗年龄相关性黄斑变性的糖的抗VEGF抗体的液体药物制剂。

公开(公告)号：WO2022268887A1

公开(公告)日：2022-12-29

申请号：PCT/EP2022/067030

申请日：2022-06-22

Applicant: FORMYCON AG

Inventor： SIGL, Rainer ,  SCHOTT, Katharina Maria

IPC: A61K39/395 ,  A61K47/26 ,  A61K9/00 ,  A61K9/08 ,  A61K47/12 ,  A61K47/18 ,  A61P35/00 ,  C07K16/28 ,  A61K39/00 ,  A61K2039/505 ,  A61K39/39591 ,  A61K47/183 ,  A61K9/0019 ,  C07K16/2818 ,  C07K2317/24 ,  C07K2317/76 ,  C07K2317/94

Abstract: The present invention relates to pharmaceutical compositions of an anti-PD1 antibody comprising acitrate buffer, one or more amino acids other than histidine and a surfactant.

公开(公告)号：WO2022184854A2

公开(公告)日：2022-09-09

申请号：PCT/EP2022/055457

申请日：2022-03-03

Applicant: FORMYCON AG

Inventor： REITER, Alwin ,  SIGL, Rainer

IPC: A61K9/00 ,  A61K9/08 ,  A61K31/14 ,  A61K38/00 ,  A61K47/02 ,  A61K47/12 ,  A61K47/14 ,  A61K47/18 ,  A61K47/26 ,  A61P31/12 ,  A61P31/14

Abstract: The present invention relates to pharmaceutical compositions of ACE2 Fc fusion proteins and therapeutic uses thereof, in particular in the treatment of infections with SARS-CoV-2.